Mimetica Overview

  • Year Founded
  • 2001

Year Founded

  • Status
  • Out of Business

  • Latest Deal Type
  • Out of Business

Mimetica General Information

Description

Developer of a drug discovery platform designed to treat acne. The company's platform is based on the rational design of small molecules that mimic natural peptide hormones, enabling users to get flawless skin.

Contact Information

Ownership Status
Out of Business
Financing Status
Formerly VC-backed
Corporate Office
  • Level 19 HWT Tower
  • 40 City Road
  • Melbourne, Victoria 3006
  • Australia
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Pharmaceuticals
Corporate Office
  • Level 19 HWT Tower
  • 40 City Road
  • Melbourne, Victoria 3006
  • Australia

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Mimetica Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
5. Out of Business 19-Apr-2021 Completed Out of Business
4. Later Stage VC 07-Mar-2014 Completed Clinical Trials - Phase 2
3. Reverse Merger 22-Oct-2013 Cancelled Generating Revenue
2. Later Stage VC 01-Jan-2013 $1.5M $1.5M Completed Generating Revenue
1. Later Stage VC 01-May-2007 Completed Generating Revenue
To view Mimetica’s complete valuation and funding history, request access »

Mimetica Patents

Mimetica Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20120141392-A1 Methods of modulating the activity of the mc1 receptor and treatment of conditions related to this receptor Inactive 27-Feb-2009
US-20140128380-A1 Methods of modulating the activity of the mc1 receptor and treatment of conditions related to this receptor Inactive 27-Feb-2009
WO-2010096853-A1 Methods of modulating the activity of the mc1 receptor and treatment of conditions related to this receptor Inactive 27-Feb-2009
WO-2010096854-A1 Methods of modulating the activity of the mc3 and/or mc4 receptors and treatment of conditions related to these receptors Inactive 27-Feb-2009
JP-2011513244-A 3-aminoalkyl-1,4-diazepan-2-one melanocortin-5 receptor antagonist Active 29-Feb-2008 C07D243/08
To view Mimetica’s complete patent history, request access »

Mimetica FAQs

  • When was Mimetica founded?

    Mimetica was founded in 2001.

  • Where is Mimetica headquartered?

    Mimetica is headquartered in Melbourne, Australia.

  • What industry is Mimetica in?

    Mimetica’s primary industry is Drug Discovery.

  • Is Mimetica a private or public company?

    Mimetica is a Private company.

  • What is Mimetica’s current revenue?

    The current revenue for Mimetica is .

  • How much funding has Mimetica raised over time?

    Mimetica has raised $7.5M.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process